Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism

Background The vacuoles, E1-enzyme, X linked, autoinflammatory and somatic (VEXAS) syndrome is an adult-onset autoinflammatory disease (AID) due to postzygotic UBA1 variants. Objectives To investigate the presence of VEXAS syndrome among patients with adult-onset undiagnosed AID. Additional studies evaluated the mosaicism distribution and the circulating cytokines. Methods Gene analyses were performed by both Sanger and amplicon-based deep sequencing. Patients’ data were collected from their medical charts. Cytokines were quantified by Luminex. Results Genetic analyses of enrolled patients (n=42) identified 30 patients carrying UBA1 pathogenic variants, with frequencies compatible for postzygotic variants. All patients were male individuals who presented with a late-onset disease (mean 67.5 years; median 67.0 years) characterised by cutaneous lesions (90%), fever (66.7%), pulmonary manifestations (66.7%) and arthritis (53.3%). Macrocytic anaemia and increased erythrocyte sedimentation rate and ferritin were the most relevant analytical abnormalities. Glucocorticoids ameliorated the inflammatory manifestations, but most patients became glucocorticoid-dependent. Positive responses were obtained when targeting the haematopoietic component of the disease with either decitabine or allogeneic haematopoietic stem cell transplantation. Additional analyses detected the UBA1 variants in both haematopoietic and non-haematopoietic tissues. Finally, analysis of circulating cytokines did not identify inflammatory mediators of the disease. Conclusion Thirty patients with adult-onset AID were definitively diagnosed with VEXAS syndrome through genetic analyses. Despite minor interindividual differences, their main characteristics were in concordance with previous reports. We detected for the first time the UBA1 mosaicism in non-haematopoietic tissue, which questions the previous concept of myeloid-restricted mosaicism and may have conceptual consequences for the disease mechanisms.

[1]  D. Kastner,et al.  Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population. , 2023, JAMA.

[2]  V. Bigley,et al.  Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience , 2022, British journal of haematology.

[3]  N. Young,et al.  VEXAS syndrome , 2022, International Journal of Hematology.

[4]  T. Cluzeau,et al.  Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report , 2022, Bone Marrow Transplantation.

[5]  K. Götze,et al.  Successful treatment with azacitidine in VEXAS syndrome with prominent myofasciitis. , 2021, Rheumatology.

[6]  B. Quesnel,et al.  Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience , 2021, Blood advances.

[7]  J. Yagüe,et al.  First Description of Late‐Onset Autoinflammatory Disease Due to Somatic NLRC4 Mosaicism , 2021, Arthritis & rheumatology.

[8]  P. Fenaux,et al.  Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry , 2021, British journal of haematology.

[9]  F. Carrat,et al.  Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients * , 2021, The British journal of dermatology.

[10]  E. Clappier,et al.  UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome. , 2021, JAMA dermatology.

[11]  J. Rossignol,et al.  Atypical splice site mutations causing VEXAS syndrome. , 2021, Rheumatology.

[12]  I. Aksentijevich,et al.  Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases , 2021, Nature Reviews Rheumatology.

[13]  A. Hoischen,et al.  Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of VEXAS patients. , 2021, The Journal of allergy and clinical immunology.

[14]  P. Evans,et al.  Novel somatic mutations in UBA1 as a cause of VEXAS syndrome , 2021, Blood.

[15]  J. Mullikin,et al.  Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. , 2020, The New England journal of medicine.

[16]  C. Calabrese,et al.  Somatic mosaicism in adult‐onset TNF receptor‐associated periodic syndrome (TRAPS) , 2019, Molecular genetics & genomic medicine.

[17]  D. Steensma Clinical consequences of clonal hematopoiesis of indeterminate potential. , 2018, Blood advances.

[18]  P. Hawkins,et al.  Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism—UK Single Center Experience , 2017, Front. Immunol..

[19]  J. Yagüe,et al.  Brief Report: Late‐Onset Cryopyrin‐Associated Periodic Syndrome Due to Myeloid‐Restricted Somatic NLRP3 Mosaicism , 2016, Arthritis & rheumatology.

[20]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[21]  E. Remmers,et al.  Cryopyrin-associated Periodic Syndrome Caused by a Myeloid-Restricted Somatic NLRP3 Mutation , 2015 .

[22]  B. Ebert,et al.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.

[23]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[24]  B. Turner Hospital , 2006 .

[25]  R. Joynt Department , 1960, Neurology.

[26]  J. Yagüe,et al.  Unexpected relevant role of gene mosaicism in patients with primary immunodeficiency diseases , 2019, The Journal of allergy and clinical immunology.